Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion
Description
Fostamatinib, a spleen tyrosine kinase (Syk) inhibitor, represents a new therapeutic opportunity for patients with immune thrombocytopenia (ITP) in Europe and Italy. However, the positioning of this drug in patient's therapeutic sequence is undefined
